Ogólnopolski program leczenia niedoboru wzrostu



Pobieranie 0.88 Mb.
Strona13/20
Data07.05.2016
Rozmiar0.88 Mb.
1   ...   9   10   11   12   13   14   15   16   ...   20

6. Piśmiennictwo


  1. Albertsson-Wikland K. Clinical trial with authentic recombinant somatropin in Sweden and Finland. Acta Paediatric Scand Suppl 1987, 331, 28-34.

  2. Aubert M.L., Arsenijevic Y., Gruaz N.M., Sizonienko P.C. Mechanisms involved in the onset of sexual amuration in the rat., w: Control of the Onset of Puberty III., pod red. Delemarre-van de Waal H.A., Plant T.M., Rees G.P., Schoemaker J., Elsevier Science Publ. B.V. (Biomedical Division), Amsterdam 1989, 191-203.

  3. Beshyah S.A., Sharp P.S., Gelding S.V. i wsp. Whole – body leucine turnover in adults on conventional treatment for hypopituitarism. Acta Endocrinol 1993; 129: 158 – 164.

  4. Blethen SL, Allen DB, Graves D. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Study Experience. J Clin Endocrinol Metab, 1996, 81, 1704-1710.

  5. Blum W.F., Ranke M.B., Keitzman K., Gauggel E., Zeisel H.J., Bierich I.R. A specific radioimmunoassay for the growth hormone (GH) dependent somatomedin binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 1990; 70: 1292 – 1298.

  6. Bolanowski M., Milewicz A. Substytucyjne leczenie hormonem wzrostu (GH) u dorosłych: wyniki, powikłania. Endokrynol Pol 1999; 50 (Suppl 2): 55 - 61.

  7. Caidahl K., Eden S., Bengtsson B.A. Cardiovascular and renal effects of growth hormone. Clin Endocrinol 1994; 40: 393-400.

  8. Chatelain P.G., Sanchez P., Saez J.M. Growth hormone and insulin- like growth factor-I treatment increase testicular luteinizing hormone receptors and steroidogenic responsiveness of growth hormone deficient dwarf mice. Endocrinology 1991; 128: 1857-1862.

  9. Cuneo R.C., Salomon F., Watts G.F., Hesp R., Souksen P.H. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metab Clin Exp 1993; 42: 1519 – 1523.

  10. De Boyer H., Blok G.J., Van Der Veen E.A. Clinical aspects of growth hormone deficiency in adults. Endocrine Rev 1995; 16: 63 – 86.

  11. de Muick Keizer-Schrama S.M.P.F., Rikken B., Wynne H.J. Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: effects on auxological and biochemical parameters. J Clin Endocrinol Metab 1992, 74, 898-905.

  12. Florini J.R., Ewton D.Z., Coolican S.A. Growth hormone and insulin – like growth factor system in myogenesis. Endocrine Rev 1996; 17: 481 – 517.

  13. Herlitz H., Jonsson O., Bengtsson B.A. Relationship between plasma growth hormone concentration and cellular sodium transport in acromegaly. Acta Endocrinol 1992; 127: 38-43.

  14. Ho K.Y., Weissberger J. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism 1990; 39: 133-137.

  15. Iranmanesh A., Lizarralde G., Veldhuis J.D. Age and relative obesity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory brust and the half life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991; 73: 1081 – 1088.

  16. Isaksson O.G.P., Lindahl A., Nilsson A., Isgaard J. Mechanism of the stimulator effects of growth hormone on longitudinal bone growth. Endocrine Rev 1987; 8: 426 – 438.

  17. Johannsson G., Rosen T., Bosaeus I., Sjostrom L., Bengtsson B.A. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996; 81: 2865 – 2873.

  18. Kinalska I., Kowalska I. Kliniczne i metaboliczne efekty działania GH – IGF-1 u dorosłych: wpływ na gospodarkę węglowodanową, lipidową, białkową i układ krzepnięcia. Endokrynol Pol 1999; 50 (Suppl 2): 69 -73.

  19. Mason H.D., Martikainen H., Beard R.W., Anyaoku U., Franks S. Direct gonadotrophic effect of growth hormone on oestradiol production by human granulosa cells in vitro. J Endocrinol 1990; 126: 4.

  20. Nishiyama K. Sugimoto T., Kai H. Stimulatory effects of growth hormone on bone resorption and osteoclast differentiation. Endocrinology 1996; 137: 35 – 41.

  21. OHalloran D.J., Tsatsoulis A., Whitehouse R.W., Holmes S.J., Adams J.E., Shalet S.M. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993; 76: 1344 – 1348.

  22. Ohlsson C., Bengtsson B., Isaksson O.G.P., Andreassen T., Slootweg M.C. Growth hormone and bone. Endocrine Rev 1998; 19: 55 – 79.

  23. Pawlikowski M. Regulacja wydzielania hormonu wzrostu (GH) i insulinopodobnego czynnika wzrostowego I (IGF-I). Endokrynol Pol 1999; 50, (supl 2): 5-10.

  24. Prinz P.N., Weitzman E.D., Cunningham G.R., Karacan I. Plasma growth hormone during sleep in young and aged man. J Gerontol 1983; 38: 519 – 524.

  25. Raben M.S.,: Preparation of growth hormone from pituitaries of man and monkey. Science 1957, 125: 883.

  26. Rappaport ED, Fife D. Sliped capital femoral epiphysis in growth hormone-deficient patients. Am J Dis Child 1985, 139, 396-399.

  27. Romer T.E. Przysadka – podwzgórze – ośrodki ponadpodwzgórzowe., w: Zaburzenia Hormonalne u Dzieci i Młodzieży., pod red. Romer T.E., Omnitech Press, Warszawa 1993: 26-50.

  28. Romer T.E. Zaburzenia wzrostu i rozwoju., w: Endokrynologia Kliniczna dla Ginekologa, Internisty i Pediatry., pod red. Romer T.E., Springer PWN, Warszawa 1998: 43 - 65.

  29. Rutherford O.M., Beshyah S.A., Johnston D.G. Quadriceps strength before and after growth hormone replacement in hipopituitary adults: Relationship to changes in lean body mass and IGF-1. Endocrinol Metab 1994; 1: 41 – 47.

  30. Sharara F.I., Gindice L.C. Role of growth hormone in ovarian physiology and onset of puberty. J Soc Gynecol Invest 1997; 4: 2 – 7.

  31. Stubbe P., Frasier S.D., Sthanke N. Growth response to recombinant human growth hormone of mammalian origin in prepubertal growth hormone-deficient chidren during first two years of treatment. Horm Res 1992, 37 (suppl 2), 28 – 36.

  32. Wilton P. Adverse events during growth hormone treatment: 5 years experience in the Kabi International Growth Study., w: Progress in Growth Hormone Therapy – 5 years of KIGS, pod red. Ranke MB, Gunnarsson R. J&J Verlag, Mannheim 1994, 291-307.

  33. Walczak M. Ocena wybranych wyznaczników procesów wzrastania i dojrzewania u wcześniaków oraz noworodków urodzonych z hipotrofią. Postępy w Neonatol. 1997, supl. 3.

  34. Walczak M., Korman E. Hormon wzrostu u wcześniaków oraz niemowląt urodzonych z hipotrofią. Endokrynologia, Diabetologia i Choroby Przemiany Materii wieku rozwojowego 2000; 6: 7 – 13.

  35. Gluckman P.D. Growth hormone and prolactin., w: Fetal and neonatal physiology., red. Polin R.A., Fox W.W., Saunders Co, Philadelphia 1992, 1785.

  36. Bozzola M., Tettoni K., Locatelli F., Radetti G., Belloni C., Autelli Z.M., Valentini R., Severi F., Tato L. Postnatal variations of growth hormone bioactivity and of growth hormone-dependent factors. Arch Pediatr Adolesc Med 1996; 150: 1068-71.

  37. Palczewska I., Niedźwiecka Z. Wskaźniki rozwoju soamtycznego dzieci i młodzieży warszawskiej. Med. Wieku Rozw. 2001, 5, (supl 1), 17-118.

  38. Wiśniewski A., Stupnicki R., Romer T.E. - dane niepublikowane.

  39. Price D.A., Ranke M.B.: Final height following growth hormone treatment., w Growth hormone over the human life span., pod red. Ranke M.B., Johann Ambrosius Barth Edition J&J, 1998, 129 - 144.

  40. Vanderschueren-Lodeweyckx M.: History of Growth Hormone Treatment and Development of the Kabi International Growth Study., w: Growth hormone over the human life span. pod red. Ranke M.B., Johann Ambrosius Barth Edition J&J, 1998, 8 - 24.

  41. Tinkline T.S., Betts P.R.: What is the current status of GH therapy in children with Turner syndrome. w Growth Hormon Therapy., pod red. Monsson J.P.. Blackwell Science, 1999, 19 - 35.

  42. Neely E.K.: Turner Syndrome., w Pediatric Endocrinology., pod red. Lifshitz F. Marcel Dekker Inc. N. York, Basel, Hong Kong, 1996, 267 - 280.

  43. Wiśniewski A., Romer T.E.: Badanie odpowiedzi wzrostowej u chorych z zespołem Turnera na leczenie hormonem wzrostu zależnie od stosowanej dawki oraz charakterystyki klinicznej i hormonalnej pacjentek. Endokrynologia, Diabetologia i Choroby Przemiany Materii wieku rozwojowego 1995, 1: 7 - 17.

  44. Wiśniewski A.: Chorzy na zespół Turnera są wśród Twoich pacjentów. Klinika, 1993, 2, 40 - 43.

  45. Wiśniewski A.: Zespół Turnera., w Endokrynologia kliniczna dla ginekologa, internisty i pediatry, pod red. Romer T.E., Springer PWN, 1998, 80 - 87.

  46. Fine R.N., Pyke-Grimme K., Nelson P.A. i wsp. Recombinant human growth hormone (rhGH) treatment of children with chronic renal failure (CRF):long-term (one to three years) outcome. Pediatr Nephrol 1991; 5: 477.

  47. Tonshoff B., Heinrich U. How safe is the treatment of uremic children with recombinant human growth hormone ? Pediatr Nephrol 1991; 5: 438 – 443.

  48. Powell D.R., Liu-Bonita F. i wsp. Effect of chronic renal failure and growth hormone therapy on the insuline-like growth factors and their binding proteins. Pediatr Nephrol. 2000, 14, 579 – 583.

  49. Stefanidis C.J. When to start recombinant human growth hormone in children with chronic renal insufficiency. Proceedings -3rd Novo Nordisk Workshop on CRI, Lausanne 1996; 48 – 51.

  50. Fine R.N., Kohaut E., Brown D i wsp. Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone. Kidney Int 1996; 49: 781 – 785.

  51. Rizzioni G., Broyer M., Brunner F.P. i wsp. Combined report on regular dialysis and transplantation of children in Europe. European Dialysis and Transplantation Association Registration Committee, 1986.

  52. Fine R.N. Recombinant human growth hormone in children with chronic renal insufficiency – clinical update: 1995. Kidney Int. 1996; 49 (suppl): 115 – 118.

  53. Mehls O., Schaefer F., Tönsshoff B. Growth disorders in chronic renal failure. Oxford for Pharmacia 1991.

  54. Said M.H., Hadi-Aissa A., Schell M. i wsp. Effect of recombinant growth hormone treatment on renal function in kidney transplant children. Pediatr Nephrol 1996; 10: 68.

  55. Romer T. E., Walczak M., Wiśniewski A. oraz pozostali członkowie Zespołu Koordynacyjnego ds. Stosowania Hormonu Wzrostu. Dziecko wolno rosnące i niskie. Standardy Medyczne 2001; 3, (7/8), 18-30.

  56. Romer T. E., Walczak M., Wiśniewski A., Roszkowska-Blaim M., Korman E. oraz pozostali członkowie Zespołu Koordynacyjnego ds. Stosowania Hormonu Wzrostu. Dzieci z zaburzonym procesem wzrastania, kwalifikowane w Polsce do leczenia hormonem wzrostu. Pediatr. Prakt. 2001; 9, (1), 41-54.

  57. Pańczyk-Tomaszewska M., Ziółkowska H., Roszkowska-Blaim M. Leczenie rekombinowanym ludzkim hormonem wzrostu dzieci z niskorosłością mocznicową. Standardy Medyczne 2000; 2, (12), 13-14.

  58. Ranke M.B., Wilton P. i wsp. Growth hormone therapy in KIGS – 10 years` experience. Johann Ambrosius Barth Verlag; Heildelberg, Leipzig 1999.

  59. Ritzen E.M. Growth hormone treatment of children with Prader-Willi syndrome as reported to KIGS: first-year growth response., w: Growth hormone therapy in KIGS – 10 years` experience., pod red. Ranke M.B., Wilton P. . Johann Ambrosius Barth Verlag; Heildelberg, Leipzig 1999, 295-304.

  60. Ranke M.B., Preece M.A. Growth hormone treatment in short children born small for gestational age: from controversy towards consensus. Horm. Res. 1997; 48 (supl. 1): 72-74.

  61. Chatelain P., de Zegher F. i wsp. Growth hormone treatment in children with Intrauterine Growth Retardation and Siver-Russel Syndrome.; ., w: Growth hormone therapy in KIGS – 10 years` experience., pod red. Ranke M.B., Wilton P. . Johann Ambrosius Barth Verlag; Heildelberg, Leipzig 1999, 305-320.


1   ...   9   10   11   12   13   14   15   16   ...   20


©absta.pl 2016
wyślij wiadomość

    Strona główna